TB e HIV nelle coorti

Similar documents
TB epidemic and progress towards the Millennium Development Goals

In 2013, around 12.9 million people living with HIV had access to antiretroviral therapy.

Epidemiology of tuberculosis in Europe. Marieke J. van der Werf European Centre for Disease Prevention and Control Amsterdam, 22 September 2014

Can we treat our way out of the HIV epidemic?

HIV/AIDS in East Asia

Tuberculosis-related deaths in people living with HIV have fallen by 36% since 2004.

HIV and Paediatrics in Central Europe

Progress on the targets of Millennium Development Goal 6 in central and eastern Europe and central Asia

Table S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations,

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

Antiretroviral Therapy Cohort Collaboration

Scaling up priority HIV/AIDS interventions in the health sector

The Impact of the Global Economic Crisis on HIV and AIDS. Carlos Avila. 7 December 2009 UNAIDS Geneva

Since the start t of the HIV/ 1980 s: 77.3 million people have be. In million people were liv

TB surveillance. Philippe Glaziou Dubrovnik, May 2009

The EACS Standard of Care initiative. The Standard of Care for HIV and Coinfections in Europe meeting in Rome: a reminder

AIDS at 25. Epidemiology and Clinical Management MID 37

Tuberculosis and HIV coinfection still a challenge in Central and Eastern Europe

TB in the SEA Region. Review Plans and Progress. Dr Md Khurshid Alam Hyder Medical Officer TB SEARO/WHO

Module 1: HIV epidemiology, transmission and prevention

Program to control HIV/AIDS

The epidemiology of tuberculosis

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

GLOBAL STATISTICS FACT SHEET 2015

HIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital

A smart and doable investment

AIDS at 30 Epidemiology and Clinical Epidemiology and Management MID 37

GLOBAL HIV STATISTICS

Towards universal access

HIV and Tuberculosis in Eastern Europe

L aderenza del trattamento e strategie

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.

The WHO END-TB Strategy

Community oriented studies. New perspectives

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

HIV behandeling, een internationaal perspectief LUT LYNEN DEPARTEMENT KLINISCHE WETENSCHAPPEN ITG

Evolving Realities of HIV Treatment in Resource-limited Settings

Progress against the HIV Epidemic: is the end in sight?

Institut Pasteur du Cambodge scientific report and 2018 prospects Rapport 2017 et programmation scientifique 2018 IMMUNOLOGY PLATFORM

Interventions to improve screening for latent TB: effectiveness and outcomes

Prevention and care towards vulnerable and stigmatized populations (MSM, drug users, sex workers)

Date of study period: April 12 May 7, 2010 and August September, 2010

Drug-resistant Tuberculosis

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control

Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018

TB/HIV Co-Infection. Tuberculosis and HIV

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs

Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016

Key issues for HIV testing and

TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.

Okinawa, Toyako, and Beyond: Progress on Health and Development

Eventi cerebro-vascolari: davvero una nuova frontiera?

Number of people receiving ARV therapy in developing and transitional countries by region,

227 28, 2010 MIDTERM EXAMINATION KEY

PART II! IMMUNE SENESCENCE!

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital

AIDS Acquired Immune Deficiency Syndrom

Annual Epidemiological Report

Immunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052

Tuberculosis surveillance in Germany. Data of the tuberculosis report 2013

The Epidemiology of Tuberculosis in Minnesota,

Annual Epidemiological Report

511,000 (57% new cases) ~50,000 ~30,000

Investing for Impact

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific

ENDING AIDS, TB AND MALARIA AS EPIDEMICS

ENDING AIDS, TB AND MALARIA AS EPIDEMICS

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

For any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,

HIV e infarto miocardico: un problema dimenticato?

Objective: Specific Aims:

Who Is Dying and Why? AIDS Mortality as a Progress Metric

Fertility Desires/Management of Serodiscordant HIV + Couples

Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study

Tuberculosis Impact in Boston Residents: 2012

IAS 2013 Towards an HIV Cure Symposium

On the Fast-Track to end AIDS. HIV & AIDS in the Post 2015 Development Agenda

HIV transmission in the migrant population. D. Paraskevis

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

Analysing clinical datasets: Challenges and pitfalls. Amanda Mocroft University College London

Summary I: TB, Opportunistic Infections, HCV/HBV Co-Infections, HPV, STI & Tumors

Outline. AIDS & HIV in the Travis County. Global estimates for adults & children end HIV incidence worldwide

Outline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Host-pathogen interactions in Multidrug-Resistant Tuberculosis

CROI 2017 Review: Hepatitis C Coinfection

Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10

Progress in scaling up HIV prevention and treatment in sub-saharan Africa: 15 years, the state of AIDS

Projected Demand for HIV Diagnostic Tests

Round table discussion Patients with multiresistant virus : A limited number, but a remarkable deal Introduction

ECDC and Spanish Ministry of Health workshop:

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

ART for prevention the task ahead

Annual Epidemiological Report

Epidemiological profiles of viral hepatitis in Italy Effects of migration

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:

Reasons why we will never forget. Andrea Antinori INMI L. Spallanzani IRCCS, Roma

Universal access to medicine: HIV and beyond

Transcription:

TB e HIV nelle coorti Antonella d Arminio Monforte Clinica di Malattie Infettive Dipartimento di Scienze della Salute Università degli Studi di Milano Presidio Ospedalero San Paolo, ASST Santi Paolo e Carlo Milano

Outline Tubercolosi in Europa Tb e HIV MDR e Eastern Europe Mortalità per Tb Dati Icona Recupero viro-immunologico in corso di ART

TB notifications by country In 2013, 64 844 TB cases were reported in the EU/EEA. The notification rate was 12.7 per 100 000 population (range 3.4 83.5). Figure 1: TB notification rate per 100 000 population by country, EU/EEA, 2013 < 5 per 100 000 5 to 9 per 100 000 10 to 19 per 100 000 20 to 49 per 100 000 50 per 100 000 Not included or not reporting

TB cases of foreign origin In 2013, the proportion of TB cases of foreign origin in the EU/EEA was 28.0% (range 0.3 94.7%). Figure 6: Percentage of TB cases of foreign origin by country, EU/EEA, 2013 < 1% 1 to 24.9% 25 to 49.9% 50 to 74.9% 75% Not included or not reporting 4

Multidrug-resistant TB among all TB cases In 2013, the proportion of TB cases with multidrugresistance in the EU/EEA was 4.1% (range 0 22.7%). Figure 9: Percentage of MDR TB among all confirmed TB cases by country, EU/EEA, 2013 < 1% 1 to 1.9% 2 to 4.9% 5 to 9.9% 10% Not included or not reporting 5

TB/HIV co-infection In 2013, the proportion HIV positive among TB cases with known HIV status in EU/EEA was 4.9% (range 0 22.6%). Figure 14: Percentage of HIV-positive cases among TB cases with known HIV status, by country, EU/EEA, 2013 < 1% 1 to 4.9% 5 to 9.9% 10% Not reporting 6

PLOS ONE DOI:10.1371/journal.pone.0145380 December 30, 2015 1 / 17 Objectives Rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-tb treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA).

1413 patients with TB

In conclusion, our analysis showed that HIV-infected patients starting cart when ART naive and with a tuberculosis diagnosis have an impaired immune recovery with cart,mainly because of differences in level of viral suppression between them and both patients with nontuberculosis AIDS and those without AIDS. Further studies need to be performed to determine whether our findings may be explained by pharmacokinetic interactions between the 2 treatments or to specific interactions between M. tuberculosis and HIV or both. Nevertheless, our results suggest that strategies aimed at preventing tuberculosis cases may increase the chances of virological and immunological response to cart

Introduction CROI 2016 Poster 751 Tuberculosis (TB) may play an important role in immune recovery and HIV replication after ART initiation among HIV-infected individuals. We examined the CD4 cell and HIV-RNA viral load changes on ART in patients without, with prevalent or a history of TB.

Baseline Characteristics- Cohere CROI 2016; Boston 22-25 February Poster 751

Results CD4 cell increases were lower in patients with prevalent and recent TB compared to patients without a TB history. This effect was more pronounced in the first months of ART and in patients with higher baseline CD4 count. Patients with prevalent TB had slower overall viral load decline especially during the first months of ART. Patients with recent TB showed a slower viral load decline only during the first 6 months of ART. Non-European, especially Sub-Saharan Africa origin, was associated with lower CD4 increases and slower HIV-RNA declines, as was female sex. Older age was associated with lower CD4 increases but faster viral load declines. CROI 2016; Boston 22-25 February Poster 751

Modelled CD4 cell trajectories (A), and HIV RNA viral load trajectories (adjusted) (B) in HIV-positive patients presenting with tuberculosis (TB) at ART start without a history of TB Fitted change for a male reference patient, 38 years, European, heterosexual, on cart at baseline A B CROI 2016; Boston 22-25 February Poster 751

Associations of CD4 cell count and HIV-RNA viral load changes after starting ART in HIV-positive patients with prevalent TB at ART start and a recent history of TB compared to patients without a history of TB

Conclusions TB had a significant effect on virological and immunological response to ART which was most pronounced during the first year of ART. CD4 cell recovery after ART start was worse in patients presenting with prevalent or recent TB. Viral load decline tended to be slower only in patients with prevalent TB. These effects were more pronounced in patients from high-tb incidence countries who may require attention in clinical management. CROI 2016; Boston 22-25 February Poster 751

TB and HIV in the cohorts: conclusions Also from data of the cohorts of HIV patients it is evident that epidemics in Eastern Europe is more dramatic, more severe and more often sustained by MDR Tb as compared to epidemics in Western Europe. In Italy, most cases of HIV-Tb occur in non Italian people, and in severely immunodepressed patients Patients with HIV-Tb have a less pronuonced immune reconsititution in the first year of ART Special attention may be required in recent TB cases starting ART